News

The neurologist in the Danish Multiple Sclerosis Center at Copenhagen University Hospital discussed the debate surrounding the use of hormone therapy in multiple sclerosis treatment, highlighting the need for more clinical evidence to support its use. [WATCH TIME: 5 minutes]

After a median follow-up of 19 months, only the physical component on the Multiple Sclerosis Impact Scale was worsened in the discontinuation group.

Findings from the study further confirmed target engagement of BHV-7000, with future plans of a potential phase 3 trial in focal epilepsy later this year.

The chief of the Movement Disorders Division at Mass General Hospital discussed the challenges medical students face in pathing their career and the importance of a strong mentor figure. [WATCH TIME: 6 minutes]

Over a 6-month treatment period, investigators observed either stabilization or improvement on outcomes of Expanded Disability Status Scale, MFIS, T25FW, and pyramidal score.

The global program head of the development unit for neuroscience at Novartis talked about the evolving landscape of mental health care for multiple sclerosis including the accessibility barrier that remains for patients in many regions. [WATCH TIME: 4 minutes]

The head of Biogen’s MS and Immunology Department Unit provided an overview of FUSION, a currently recruiting study assessing the efficacy and safety of BIIB091 as a monotherapy and in combination with diroximel fumarate.

With the approval, zilucoplan becomes the first once-daily subcutaneous C5 complement inhibitor available for adults with generalized myasthenia gravis.

During the open-label treatment period, 83% of patients with idiopathic hypersomnia who completed treatment saw a significant reduction in sleepiness, with an average Epworth Sleepiness Scale change of -9.4 points.

Mark I. Boulos, MD, BSc, FRCP, CSCN, MSc, associate professor of medicine, division of neurology, Institute of Medical Science, University of Toronto, talked about a comprehensive meta-analysis aimed to determine normal mean sleep latency values to accurately help clinicians with interpreting sleep test results.

The pediatric neuromuscular neurologist at Arkansas Children's Hospital and associate professor of pediatrics at the University of Arkansas for Medical Sciences talked about findings from a phase 1/2 study on dosing 3 pediatric patients with Duchenne muscular dystrophy with REGENXBIO’s RGX-202. [WATCH TIME: 4 minutes]

In a recent clinical trial, patients who received SaiLuoTong showed improvements in aspects of memory and executive function including delayed episodic memory retrieval, switching between cognitive concepts, higher-level divided attention, and multitasking compared with placebo.

Episode 38 of the AUPN Leadership Minute features Muhammad "Mud" Alvi, MD, of West Virginia University Robert C. Byrd Health; and David B. Watson, MD, of West Virginia University Robert C. Byrd Health. [WATCH TIME: 5 minutes]

Over an 11-week treatment period, patients on pitolisant experienced improvements in secondary outcomes of behavioral symptoms, behavioral disturbances, and hyperphagia.

The senior neurologist at the University Hospital Center of Nice in France talked about a digital tool developed to monitor disability more accurately in patients with multiple, especially during the early stages of the disease. [WATCH TIME: 5 minutes]

Over a 24-month follow-up, investigators observed increased ganglion cell loss that could potentially be associated with an enhanced risk of developing progression without relapse activity.

The director of the neurology residency program and assistant professor of neurology at the University of South Alabama College of Medicine shared his insights from a year’s worth of using a serum biomarker test for the diagnosis of multiple sclerosis. [WATCH TIME: 5 minutes]

Solanezumab did not slow the progression of preclinical Alzheimer disease as compared with placebo on the basis of the primary or secondary cognitive and functional end points over a 4.5-year treatment period.

Hammer, a patient advocate living with acute flaccid myelitis, discussed the language around neurologic disability, and how the conversations should shift going forward. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic, provided comment on a recently published randomized controlled trial assessing the therapeutic potential of an augmented reality program for postural instability and gait dysfunction in Parkinson disease.

AOC 1001 consistently demonstrated directional improvements across multiple aspects of myotonic dystrophy type 1, including measures of myotonia, strength, function, and patient reported outcome.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the European Committe for Treatment and Research in Multiple Sclerosis.

In preclinical data, treatment with PGN-EDODM reduced pathogenic nuclear foci by 54% per nuclei and liberated muscleblind like splicing regulator 1, resulting in a greater than 68% correction of downstream transcript missplicing events.

Data from a US database suggest that patients who switched to eculizumab (Soliris; Alexion) significantly reduced their hospitalization, days hospitalized, and documented comorbidities.

Neurology News Network for the week ending October 14, 2023. [WATCH TIME: 3 minutes]

The head of Biogen’s MS and Immunology Department Unit discussed FUSION, a new phase 2, 2-part study assessing the efficacy and safety of BIIB091, an investigational Bruton’s tyrosine kinase inhibitor. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 13, 2023.

The decision opens the door for greater access to PET imaging that can assist in timely diagnosis of Alzheimer disease and facilitate with appropriate treatment decisions.

Over a 6-month period, ofatumumab-treated patients met the primary end point of no change or reduction in the number of gadolinium-enhancing lesions on MRI.